07.27.26 -- Continuous Manufacturing As A Powerful Productivity Lever

Integrated stable expression strategies accelerate biologics material generation, improving scalability, consistency, and early developability insights while reducing bottlenecks, variability, and risks.

Explore how lipid nanoparticles are driving breakthroughs in cell therapy, from mRNA-based immune cell engineering to genome editing for CAR T cells and HSPCs from leading experts.

For successful scale-up, see how optimizing process parameters such as attachment methods, gassing, and agitation can help reduce cell environmental stress, ultimately improving productivity.

Unlock superior non-viral CAR T manufacturing outcomes by combining gentle microbubble T cell isolation with advanced electroporation. Examine how this approach boosts cell viability.

Refine media and buffer prep with filtration that removes particles, reduces bioburden, and safeguards sterility — protecting processes, preventing contamination, and consistent biopharma performance.

This presentation shows how enhanced glutamine synthetase selection stringency, combined with a high-strength gene promoter, provides greater control over gene expression and supports development.

Learn key ways to cut biologics manufacturing costs through smarter process design, material choices, and supply resilience — driving more efficient, reliable, and commercially sustainable production.

Discover how our optimized CHO K1 cell lines achieved up to an 80% increase in titer while maintaining product quality through molecule-specific process development strategies.

Whole-well imaging streamlines clone selection by enabling rapid, automated analysis of single-cell growth and morphology, which reduces manual effort and improves reproducibility.

Maximize mesenchymal stem cell expansion with a simplified culture process. New data demonstrates a high-performance, xeno-free media that eliminates the need for coatings or media exchanges.

Observe the application of a platform in creating CHO cell lines for manufacturing multi-chain biologics, emphasizing the uniformity of the pools in terms of titer and the rapid selection.